Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News WAVE Life Sciences Ltd WVE

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and... see more

Current News (NDAQ:WVE)

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

GlobeNewswire 4 days ago

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 11 days ago

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewswire December 9, 2025

Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewswire December 8, 2025

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

GlobeNewswire December 8, 2025

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

GlobeNewswire December 7, 2025

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 10, 2025

Wave Life Sciences to Present at Upcoming Investor Conferences

GlobeNewswire November 7, 2025

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

GlobeNewswire November 4, 2025

Bullboard Posts (NDAQ:WVE)

Using technical analysis for this stock.

This stock is signalling strength to the upside for shareholders,so good luck to all of you
coolfooldumbguy - 10 days ago

Wave Life Sciences Ltd. (WVE): Unlocking the Potential of RN

http://beyondspx.com/2024/08/02/wave-life-sciences-ltd-wve-unlocking-the-potential-of-rna-medicines/
MikeTester - August 3, 2024

WVE.... On watch

$6.00 Cheers !
Iseneschal - December 14, 2022

WVE stock

Did alot of research on this company and bought awhile ago because of the diseases they were chasing to treat.  But why is it...
philip1 - September 18, 2020